bioAffinity Technologies Files 8-K on Equity Sales
Ticker: BIAFW · Form: 8-K · Filed: Mar 8, 2024 · CIK: 1712762
Sentiment: neutral
Topics: equity-sale, definitive-agreement, unregistered-securities
Related Tickers: BIAF
TL;DR
BIAF sold unregistered equity, check the details.
AI Summary
On March 6, 2024, bioAffinity Technologies, Inc. entered into a material definitive agreement related to the sale of unregistered equity securities. The company, incorporated in Delaware with its principal office in San Antonio, TX, filed this 8-K report detailing these events.
Why It Matters
This filing indicates potential dilution or capital raising activities for bioAffinity Technologies, which could impact its stock price and financial structure.
Risk Assessment
Risk Level: medium — Filings related to unregistered equity sales can signal financial needs or dilution, requiring closer examination by investors.
Key Numbers
- 001-41463 — SEC File Number (Identifier for the company's filings with the SEC)
- 46-5211056 — IRS Employer Identification Number (Tax identification number for the company)
Key Players & Entities
- bioAffinity Technologies, Inc. (company) — Registrant
- March 6, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- San Antonio, TX (location) — Business address city and state
FAQ
What type of unregistered equity securities were sold by bioAffinity Technologies?
The filing indicates the sale of "CommonStockParValue.007PerShareMember" and "TradeableWarrantsToPurchaseCommonStockMember" on March 6, 2024.
What is the par value of the common stock mentioned in the filing?
The common stock mentioned has a par value of $0.007 per share.
What is the filing date of this 8-K report?
The 8-K report was filed on March 8, 2024.
What is the primary business of bioAffinity Technologies, Inc. according to the SIC code?
The Standard Industrial Classification (SIC) code provided is 8731, which corresponds to SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH.
Where is bioAffinity Technologies, Inc. incorporated?
The company is incorporated in Delaware.
Filing Stats: 2,411 words · 10 min read · ~8 pages · Grade level 14.4 · Accepted 2024-03-08 17:00:45
Key Financial Figures
- $0.007 — common stock (the "Shares"), par value $0.007 per share ("Common Stock") and (ii) in
- $1.64 — on Warrants") with an exercise price of $1.64. Such registered direct offering and co
- $2.5 m — from the Transactions of approximately $2.5 million, before deducting fees to the Pla
- $1 — at an exercise price per share equal to $1.64, which is equal to the exercise pric
- $3.0625 — tial public offering will be reduced to $3.0625. Item 9.01. Financial Statements and E
Filing Documents
- form8-k.htm (8-K) — 66KB
- ex1-1.htm (EX-1.1) — 141KB
- ex4-1.htm (EX-4.1) — 122KB
- ex4-2.htm (EX-4.2) — 115KB
- ex5-1.htm (EX-5.1) — 12KB
- ex10-1.htm (EX-10.1) — 266KB
- ex10-2.htm (EX-10.2) — 21KB
- ex99-1.htm (EX-99.1) — 16KB
- ex99-2.htm (EX-99.2) — 16KB
- ex5-1_001.jpg (GRAPHIC) — 7KB
- ex99-1_001.jpg (GRAPHIC) — 19KB
- ex99-2_001.jpg (GRAPHIC) — 29KB
- 0001493152-24-009438.txt ( ) — 1234KB
- biaf-20240306.xsd (EX-101.SCH) — 4KB
- biaf-20240306_def.xml (EX-101.DEF) — 26KB
- biaf-20240306_lab.xml (EX-101.LAB) — 36KB
- biaf-20240306_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 8, 2024 BIOAFFINITY TECHNOLOGIES, INC. (Registrant) By: /s/ Maria Zannes Name: Maria Zannes Title: President and Chief Executive Officer